Literature DB >> 17931144

Adjuvants: progress, regress and pandemic preparedness.

Gregory M Glenn, Derek T O'Hagan.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17931144     DOI： 10.1586/14760584.6.5.651

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


× No keyword cloud information.
  5 in total

1.  Recent advances in the development of immunotherapies for tauopathies.

Authors:  Kiren Ubhi; Eliezer Masliah
Journal:  Exp Neurol       Date:  2010-10-21       Impact factor: 5.330

2.  Vaccine adjuvants alter TCR-based selection thresholds.

Authors:  Laurent Malherbe; Linda Mark; Nicolas Fazilleau; Louise J McHeyzer-Williams; Michael G McHeyzer-Williams
Journal:  Immunity       Date:  2008-05-01       Impact factor: 31.745

3.  Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes.

Authors:  Eric K Chea; Alberto Fernández-Tejada; Payal Damani; Michelle M Adams; Jeffrey R Gardner; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  J Am Chem Soc       Date:  2012-08-06       Impact factor: 15.419

4.  Multiparameter telemetry as a sensitive screening method to detect vaccine reactogenicity in mice.

Authors:  Margarete Arras; Daniel L Glauser; Paulin Jirkof; Andreas Rettich; Benjamin Schade; Paolo Cinelli; Daniel D Pinschewer; Mathias Ackermann
Journal:  PLoS One       Date:  2012-01-19       Impact factor: 3.240

Review 5.  Recent Progress in Dendritic Cell-Based Cancer Immunotherapy.

Authors:  Kazuhiko Matsuo; Osamu Yoshie; Kosuke Kitahata; Momo Kamei; Yuta Hara; Takashi Nakayama
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.